{"ticker": {"uuid": "660cc28a-3dbc-473d-97f7-042ca4cdce85", "symbol": "CRVS", "name": "Corvus Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Corvus Pharmaceuticals (CRVS) Proxy filing Summary", "summary": "Corvus Pharmaceuticals (CRVS) has released its proxy filing summary, outlining key proposals for its upcoming virtual annual meeting on April 24, 2026. Shareholders will vote on the election of two Class I Directors, the ratification of PricewaterhouseCoopers LLP as the independe", "url": "https://quartr.com/events/corvus-pharmaceuticals-crvs-proxy-filing_onjxu49M", "source_name": "Quartr", "published_at": "2026-07-11T02:39:29", "published_display": "11 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) Q4 2024 earnings summary", "summary": "Corvus Pharmaceuticals (CRVS) reported an increase in Q4 2024 R&D expenses to $6M, primarily due to higher soquelitinib clinical trial costs, resulting in a net loss of $12.1M. The company's cash and equivalents totaled $52M, providing a financial runway into Q1 2026. Corvus is a", "url": "https://quartr.com/events/corvus-pharmaceuticals-inc-crvs-q4-2024_onjx2UyW", "source_name": "Quartr", "published_at": "2026-07-09T02:09:34", "published_display": "09 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) Q1 2025 earnings summary", "summary": "Corvus Pharmaceuticals reported on its Q1 2025 earnings, highlighting positive Phase I trial results for soquelitinib in atopic dermatitis and its advancement into multiple indications. The company's operational runway is extended into Q4 2026 due to warrant exercises, and it ant", "url": "https://quartr.com/events/corvus-pharmaceuticals-inc-crvs-q1-2025_onjx27KN", "source_name": "Quartr", "published_at": "2026-07-08T14:10:23", "published_display": "08 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump?", "summary": "Corvus Pharmaceuticals (CRVS) has seen significant share price growth, with its stock closing at $13.05 and a market value of $1.09 billion. Despite this surge, a prevailing narrative suggests the company is 62.7% undervalued, with a fair value target of $35 given its potential i", "url": "https://www.sahmcapital.com/news/content/is-corvus-pharmaceuticals-crvs-still-undervalued-after-its-share-price-jump-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-28T10:10:35", "published_display": "28 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CRVS)", "summary": "This article provides an overview of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) stock, including its current price, performance, and analyst forecasts. It details financial data such as market capitalization, earnings per share, and revenue, as well as highlighting upcoming earn", "url": "https://www.tradingview.com/symbols/NASDAQ-CRVS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T15:11:23", "published_display": "27 Jun 2026 15:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals, Inc. Actuals & Estimates (BX:C17)", "summary": "This article provides financial actuals and estimates for Corvus Pharmaceuticals, Inc. (C17) traded on the BX Swiss exchange. It details analyst price targets, upcoming earnings reports, past earnings and revenue figures, and company information including employee count and divid", "url": "https://www.tradingview.com/symbols/BX-C17/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:29", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Corvus Pharmaceuticals, Inc. \u2013 NASDAQ:CRVS", "summary": "This article focuses on the enterprise value to revenue forward metric for Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS). It appears to be a financial data point or analysis offered by TradingView, indicating a specific valuation multiple for the company. The content primarily high", "url": "https://www.tradingview.com/symbols/NASDAQ-CRVS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:33", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Corvus Pharmaceuticals, Inc. \u2013 NASDAQ:CRVS", "summary": "This article provides a brief financial data point regarding the \"Price to sales forward\" for Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS). It appears to be an excerpt from a financial data platform, indicating the value and change for this metric, presented without additional det", "url": "https://www.tradingview.com/symbols/NASDAQ-CRVS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T11:09:51", "published_display": "25 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Corvus Pharmaceuticals, Inc. \u2013 NASDAQ:CRVS", "summary": "This article provides the \"Price to book forward\" financial metric for Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS). It lists \"Period,\" \"Value,\" \"Change,\" and \"Change %\" as data points, indicating financial performance. The content is brief and appears to be a data", "url": "https://www.tradingview.com/symbols/NASDAQ-CRVS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T05:42:18", "published_display": "25 Jun 2026 05:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQTjNobXFfdHZQaC1BMElXcGhNVVFsaVhEWHNPb0RDZjI4dnpqYUhVNzZPem1XQnlvYnh1YmVtU1FIaFBCVGRxaXpuYzZrVDNWZjVteW9fM2xQUnlWcThkOHZGcnEzZm9OSGdtWWxXeEFOaENzcW9ocjhReFFaVU44RTZndHZCWk13S1FPcG5oN0k5c1BqLVN5Sk1ZZXM0NUNfMDZJMTJKaENaRUtVUmI5b0U0NTZUdndIcUYwellzWkNGWmdo?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Corvus Pharmaceuticals Inc (CRVS), highlighting analyst ratings, price targets, and past and projected EPS. Based on ratings from 7 analysts, most recommend a \"Buy\" trend for CRVS, with a target price of USD 14.00 and an upside space", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crvs/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:07", "published_display": "18 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Inc (CRVS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Corvus Pharmaceuticals Inc (CRVS), including its PE, PB, PS, and PCF ratios. However, the company has not yet disclosed the relevant data for these valuation metrics. The page also displays the current stock price, market capitalizat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crvs/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:07", "published_display": "18 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buys Additional US$250k In Corvus Pharmaceuticals Stock", "summary": "David Moore, an Independent Director at Corvus Pharmaceuticals, recently bought an additional US$250k worth of stock at US$11.53 per share, increasing his holdings. This transaction marks the largest insider purchase in the last twelve months, indicating continued confidence in t", "url": "https://www.sahmcapital.com/news/content/insider-buys-additional-us250k-in-corvus-pharmaceuticals-stock-2026-06-17", "source_name": "Sahm", "published_at": "2026-06-17T17:40:08", "published_display": "17 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Inc (CRVS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides details on the dividend and stock split history for Corvus Pharmaceuticals Inc (CRVS). It states that the company has distributed $0.00 in dividends over the past five years and reports \"No Data\" for both dividend payouts and stock splits, indicating no such", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crvs/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T03:40:23", "published_display": "17 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Inc (CRVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Corvus Pharmaceuticals Inc (CRVS) based on business segments and regional contributions. However, it indicates that the relevant financial data for such a breakdown has not been disclosed by the company. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crvs/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T03:40:23", "published_display": "17 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Corvus Pharmaceuticals, Inc. Insider Trading Activity", "summary": "Corvus Pharmaceuticals director Ian T. Clark received a grant of 15,000 stock options with an exercise price of $11.60 per share, expiring on June 11, 2036. These options represent compensation and will vest on the earlier of the first anniversary of the grant date or the company", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-779203eb094d.html", "source_name": "Stock Titan", "published_at": "2026-06-16T07:09:38", "published_display": "16 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus (CRVS) director awarded options for 15,000 shares at $11.60", "summary": "Corvus Pharmaceuticals director Richard van den Broek was granted options to purchase 15,000 shares of common stock at an exercise price of $11.60 per share. These options will vest in a single tranche on the earlier of one year from the grant date or the company's 2027 annual st", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-e1e6bc06f2c7.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:39:33", "published_display": "16 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) director buys 21,700 shares and receives 15,000-share option", "summary": "Corvus Pharmaceuticals director David Scott Moore purchased 21,700 shares of common stock at $11.5316 per share in an open-market transaction, increasing his direct holdings to 21,700 shares. Additionally, he was granted a stock option for 15,000 shares at an exercise price of $1", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-aaa71e046de8.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:09:38", "published_display": "16 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Corvus (CRVS) receives grant of 15,000 stock options", "summary": "Corvus Pharmaceuticals director Peter A. Thompson has been granted 15,000 stock options with an exercise price of $11.60 and an expiration date of June 11, 2036. These options vest on the earlier of the first anniversary of the grant date or the 2027 annual stockholders\u2019 meeting,", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-a39606e23bf4.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:38", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) director receives grant of 15,000 stock options", "summary": "Corvus Pharmaceuticals director Linda Grais was granted 15,000 stock options with an exercise price of $11.6000 per share, expiring on June 11, 2036. These options will vest and become exercisable 100% on the earlier of the first anniversary of the grant date or the company\u2019s 202", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-7b72de75124d.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:38", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) Is Up 7.3% After Promising Soquelitinib Data And Extended Cash Runway", "summary": "Corvus Pharmaceuticals' stock rose 7.3% following promising Phase 1 results for its oral ITK inhibitor soquelitinib in atopic dermatitis, which also extended its cash runway into Q2 2028. The data showed early efficacy and a clean safety profile, supporting the drug's potential i", "url": "https://www.sahmcapital.com/news/content/corvus-pharmaceuticals-crvs-is-up-73-after-promising-soquelitinib-data-and-extended-cash-runway-2026-06-15", "source_name": "Sahm", "published_at": "2026-06-15T18:41:44", "published_display": "15 Jun 2026 18:41", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corvus-pharmaceuticals-faces-key-soquelitinib-220944054.html", "source_name": "Simply Wall St.", "published_at": "2026-06-14T22:09:44+00:00", "published_display": "14 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPcDV0azZYLXRMTVRWM2VnclJCR3BMbVZWS2R2d3ZSNE5IM29mZkJIMEVQOEZZYXVIVm5xMTBrZGtFMUU5QVhCakYzOXc1c3BZWHY4aF9UVkNDNzV3NnlWMW1hR0czOWZpRFdQUWZDMXhnLUxBUndtLWJhX3FzMEJCRkZDOTRmd3F5MDQ5VmZNb3h4UFJXbkl4UUNWNU95M0NFWnY0?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) posts 2026 annual shareholder meeting voting outcomes", "summary": "Corvus Pharmaceuticals (CRVS) has reported the results of its 2026 Annual Meeting of Stockholders. Key outcomes include the election of Class I directors Richard A. Miller and Linda S. Grais, the ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and n", "url": "https://www.stocktitan.net/sec-filings/CRVS/8-k-corvus-pharmaceuticals-inc-reports-material-event-6cac183592ea.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:40:15", "published_display": "12 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Hikes on Position in Angel", "summary": "Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) announced its participation in a new $13.5 million financing round for its Chinese collaboration partner, Angel Pharmaceuticals Ltd. Corvus, already Angel Pharma's largest shareholder, is investing $5 million to support the development ", "url": "https://www.baystreet.ca/stockstowatch/23444/Corvus-Hikes-on-Position-in-Angel", "source_name": "Baystreet.ca", "published_at": "2026-06-10T02:39:01", "published_display": "10 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRVS - Corvus Pharmaceuticals Inc Stock Price and Quote", "summary": "This article provides a detailed stock overview for Corvus Pharmaceuticals Inc (CRVS), including its current stock price, financial metrics, analyst ratings, and recent news history. It lists key financial data such as market cap, income, sales, and employee count, alongside perf", "url": "https://finviz.com/stock?t=CRVS", "source_name": "Finviz", "published_at": "2026-06-09T14:13:15", "published_display": "09 Jun 2026 14:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China", "summary": "Corvus Pharmaceuticals announced an additional $5 million investment in its Chinese collaboration partner, Angel Pharmaceuticals, as part of a $13.5 million financing round. This funding will advance the clinical development of soquelitinib in China for atopic dermatitis and asth", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corvus-pharmaceuticals-announces-additional-investment-113000611.html", "source_name": "Market source", "published_at": "2026-06-09T14:09:54", "published_display": "09 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$13.5M bet on soquelitinib: China eczema and asthma trials move ahead", "summary": "Corvus Pharmaceuticals is investing $5 million in a new $13.5 million financing round for its China partner, Angel Pharmaceuticals. This investment will support the development of soquelitinib for atopic dermatitis and asthma in China, funding an ongoing Phase 1b/2 atopic dermati", "url": "https://www.stocktitan.net/news/CRVS/corvus-pharmaceuticals-announces-additional-investment-in-angel-xu1c8ylvg7oo.html", "source_name": "Stock Titan", "published_at": "2026-06-09T11:39:24", "published_display": "09 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness", "summary": "Corvus Pharmaceuticals (CRVS) has seen significant short-term share price declines despite strong long-term gains, leading to investor questions about its valuation. While a narrative fair value of $35 suggests it's 65.5% undervalued, the P/B ratio at 4.2x (compared to an industr", "url": "https://www.sahmcapital.com/news/content/assessing-corvus-pharmaceuticals-crvs-valuation-after-strong-one-year-gains-and-recent-share-price-weakness-2026-06-02", "source_name": "Sahm", "published_at": "2026-06-02T11:39:50", "published_display": "02 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corvus-pharmaceuticals-present-2026-jefferies-200100281.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T20:01:00+00:00", "published_display": "20 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust", "summary": "Dr. Richard A. Miller, President and CEO of Corvus Pharmaceuticals, Inc. (CRVS), reported indirect open-market purchases of 6,932 shares of the company's common stock through the Miller-Horning Family Trust. These transactions, which occurred on May 18, 2026, involved purchases a", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-395e720756a3.html", "source_name": "Stock Titan", "published_at": "2026-05-20T20:40:35", "published_display": "20 May 2026 20:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNQTJlYmxwUk1rUXJ5QUdHV3lMSlJMR1k3ZkJ1WHd5U0M3TnhsVlUwVW5aWExubEJEdU03RHB0a1NTN19FV1ltUDhEUE1oc3Y3R002UXNFcmR1SkhEc3IwSm5WM0RjRFpUZk5yS1Zra1g5SWdJT1VpeHVSUFhDMEhvOHA2eEpBd0FFWUNxQW5QV21NdkxTNk9NRG5TQjB1Q0g5ZkpyOUdJbHE3ZWhmbWhyVnh6NHFOa2x3VmJ5VDNB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boxer Capital\u2019s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech\u2019s Next Phase", "summary": "", "url": "https://finance.yahoo.com/m/40edc832-292e-35a2-abd5-ebf64753a5d0/boxer-capital%E2%80%99s-%2418-million.html", "source_name": "Motley Fool", "published_at": "2026-05-17T20:46:06+00:00", "published_display": "17 May 2026 20:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corvus-pharmaceuticals-presents-soquelitinib-phase-110000712.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:00:00+00:00", "published_display": "14 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus drops on trial data for eczema therapy (CRVS:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQVGlsTlBxT0tKZUMwYW1RV0JhMUxFWjlpYjZqY05STnp5R0p6akRFTmU4cUtfeXE0SnpDVUtQZXllNE9PbVZEMGkxajlJV0ZfRl9qWGZleDFDbWkwX2JnZzIySFVtenBOaVg1ZU9Mc00xb2V3MHo2N183MzJkMzhtbUJn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Corvus Pharmaceuticals (CRVS) After A 335% One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZjFBNTA2c3BXTmtVTnVzR0dRRmVDcDczQzdhXy1yVlZWN2ZnVDZFTmc5OUUtS045cl9iNFU2b1hqdkZ5aHFLX1VlclJVR1NFRThuM015TUo2cHlDVDRNeEJScHdpcE8xVzRKaXlKNGlBcjNOVThwZjIwM0o0Z2xMX3JhblV3dGpPTFUzX3dUblRfS2hqdzdVUDF4NTV3QTJN?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_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?oc=5", "source_name": "The Manila Times", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/corvus-q1-earnings-snapshot-204438527.html", "source_name": "Associated Press", "published_at": "2026-05-07T20:44:38+00:00", "published_display": "07 May 2026 20:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Goldman Sachs initiates Corvus Pharmaceuticals stock with buy rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPdE1GRzlnUWQySWxCcUVzNktBYjF0WkF1YUF4eHY3Zm11dkgxSWtuY2JOQUhZc2ttaHQ5WDhoNG5QbGYyYk1MV1BxdTg4cGxiek9YdDBCRmM5NVBnai1oZkNGRGxBN2pQQUpJdmp6NVlxTzNjWHJDY2poaUFlNDJieWxqZi12TkRuSVR5UGNnV0lvY0JicXEwOV93RE85bFVNemQ0RVhvX2VZQkxjQnBoWFgzRDVtaS14QVZrOU40VmhWUUdlX3g4?oc=5", "source_name": "Investing.com", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus jumps as Goldman Sachs initiates at Buy on lead asset", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQcHQ0NW1fdklOTjVMSGk3RF9Kd05QbE1VUlBOdWV3YkZ0TnYwVGxIYVVpTmE1d01xOWhMa0JvZk1jTzkzX2J6c05lZXZIczZ0X2QzU2U0dEZBeEhsZS1tc2ZIakNDNTB5cEQyaFMxSkNlanU2QVg1N1BuZGlMbnlkRVJmZTFFR2s2VDU2OVU1ekNORlN4RGJKVnZXa2FWQnM?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Corvus Trials Progress And Cash Raise Reframe Soquelitinib Risk Reward Profile", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever \u2014 What Went Wrong?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOeXBrZ0ZtREpkbk50aEZpbnd6M3hiUzNFY2ktWkZUSGJ0dGFDbUR6SW9RU1hvM0tfbFdzSS1rZ2drZ2lHNDlzQUc3bWw0Yi1Hd0FaS3c1UzB6YUtvNFZJb2RkemlNZTBfeXNIZGN6bGxhYUxicnFoTlI4eGxoeklaTDl2X2s1cWM0Rno3VXNkY1E3TTJmRnFjZmx3MEFrY29yeXNsNkc5SmNBd1dIcl8zdnVpZjREWGZCNDh5RlRTQVlYQQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYVJ0U1hGTmJZWlhVRW5MTnpWN2FoUjkwWEFPOHBiLWVFa1FJZXNad0d0dTB6OEJjTklOeHZfa2xvb1BfTDAxNjkxQVoxX0FXQTh4ekxjcmkteHNpal9DZlo4ckZwWFNCQ3dRc09MSm5hVXc5OS1HSTRnM3Q1UjhiYWpKdjBVSGJwMTJhaHVORjltQUR1?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNRTRzbDVaNzROU1NFRUhpSFpnMGhuc0xaNEVnc19MMkZHUjhodjFHQ295eUdxUl9KOUV6RFdfeUNUYzZNT2owY3ZraWdKVGVZdnBuRkk2VzlsYTg3azJ5ZHZyVE42SWFVSzNCWE9EUzFhT1NsdjhPVk54bmNuU2s3Zkl4ZkV1QjcxNXQ1Sm1tUQ?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNS01ZNEtTeGtuWTFNYWlXQWVDY180Tjc1a1F3MFFRQXZxSUFIdlJnQldZZGxWcjZMVEE2dHVBd3lSTlRNUjF3ZGJUOTBqOTFRSjcwa1ctVGdOekNtYmxSektkLWtoRXZwWE9FNHFwV095b2M3dXk1Yl8xTGExM1JVYXRlcVBzYlFG?oc=5", "source_name": "Market source", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQczAzanFtdUpvY0JzYlZSZFVNeWtrZlh3bXZDVDBzU0VaVS1hdm5hWExTN2xZWjlRUHB1aDE4VDQ3Q1lhbkJCZVh1cVR1X1NTYTdqTUJSMWUyZmhkYTNFSzR4bjZQSTFCVG5IMjJ2cmpnYUxXYld3V1hkOGRvN0tEbTZ1ZTBZXzZ6YjNiUGl1aXJfdFN1QkxNR2ZoN3pIYlJNWG5EOG4yNkstM05jNWcwWUQ5ZW5sS2c0OXpyUDZn?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-22T11:35:23+00:00", "published_display": "22 Jan 2026 11:35", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Corvus Pharmaceuticals (CRVS) Valuation After Positive Soquelitinib Phase 1 Atopic Dermatitis Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNV3E4b3k4bE5TNWFrWUhoN2Z1RV9sZmpmenE3Si05c01NUVl3SWhzOTNmX3B5UFRmSko3RG51TXRIMHBpWjlQcERmRjFzNXVTeXZiM19SSFU1TWs2X21BcVlic1pGUWs2Q1hFYXBKeXhyVUxoZnpUU1ZCd0JYS29tbWdOaVUtNEpBR2dGdmlVbjAwc2Z2dEpPaQ?oc=5", "source_name": "Market source", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What made Corvus stock double on Tuesday and is it sustainable?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVUtBVnQyeVZIbzFBMzF5cHQtY2N6dTVxa1RhdXdldjRrWTBEcU03QS14OHdWYy1EcGZiQllWRGdKWDZJUDIxWVdJdVViVVpIN3lHV0VPR0k1RXpHQVhqcExkRTBVNWZQMzlKdnlXY05WbWpybDRQUm9rZ1gzUjdCd2dnR054OVU5Z1BvZUJWSTNjbS1yTkh4U1hlVHhjS0dVTVVHbngtU2JpYWZoQ2dZSTV5VnhvTFIxaHEw?oc=5", "source_name": "TradingView", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharma stock falls after announcing $150 million offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPOUtvZ2VKbHNUV3I2QnJGdHFQMXpkRS1kM3hXNkZsLUdLUmtWSk10MTYxTE85X21IZHVXajdYQUZLR2JqTG5MT2VycTRtc3oycmlxQ0VidWtMUHhXa2VTdjBYOVFUY21EZGtoa3A2WE56V2VzdEp6X0JheEVyQURDYkxQU2xxR1J4b3hzZkhyWWcyUDZEVmw0RUF1VGNQd3JTajNxM0h6Q3hKeWhOcFMzd2VLRmZxdmgtczNwWjVvZWMyYnc?oc=5", "source_name": "Investing.com", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Both retail investors who control a good portion of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) along with institutions must be dismayed after last week's 9.3% decrease", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Corvus Pharmaceuticals (CRVS) Proxy filing Summary", "summary": "Corvus Pharmaceuticals (CRVS) has released its proxy filing summary, outlining key proposals for its upcoming virtual annual meeting on April 24, 2026. Shareholders will vote on the election of two Class I Directors, the ratification of PricewaterhouseCoopers LLP as the independe", "url": "https://quartr.com/events/corvus-pharmaceuticals-crvs-proxy-filing_onjxu49M", "source_name": "Quartr", "published_at": "2026-07-11T02:39:29", "published_display": "11 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) Q4 2024 earnings summary", "summary": "Corvus Pharmaceuticals (CRVS) reported an increase in Q4 2024 R&D expenses to $6M, primarily due to higher soquelitinib clinical trial costs, resulting in a net loss of $12.1M. The company's cash and equivalents totaled $52M, providing a financial runway into Q1 2026. Corvus is a", "url": "https://quartr.com/events/corvus-pharmaceuticals-inc-crvs-q4-2024_onjx2UyW", "source_name": "Quartr", "published_at": "2026-07-09T02:09:34", "published_display": "09 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) Q1 2025 earnings summary", "summary": "Corvus Pharmaceuticals reported on its Q1 2025 earnings, highlighting positive Phase I trial results for soquelitinib in atopic dermatitis and its advancement into multiple indications. The company's operational runway is extended into Q4 2026 due to warrant exercises, and it ant", "url": "https://quartr.com/events/corvus-pharmaceuticals-inc-crvs-q1-2025_onjx27KN", "source_name": "Quartr", "published_at": "2026-07-08T14:10:23", "published_display": "08 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump?", "summary": "Corvus Pharmaceuticals (CRVS) has seen significant share price growth, with its stock closing at $13.05 and a market value of $1.09 billion. Despite this surge, a prevailing narrative suggests the company is 62.7% undervalued, with a fair value target of $35 given its potential i", "url": "https://www.sahmcapital.com/news/content/is-corvus-pharmaceuticals-crvs-still-undervalued-after-its-share-price-jump-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-28T10:10:35", "published_display": "28 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CRVS)", "summary": "This article provides an overview of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) stock, including its current price, performance, and analyst forecasts. It details financial data such as market capitalization, earnings per share, and revenue, as well as highlighting upcoming earn", "url": "https://www.tradingview.com/symbols/NASDAQ-CRVS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T15:11:23", "published_display": "27 Jun 2026 15:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals, Inc. Actuals & Estimates (BX:C17)", "summary": "This article provides financial actuals and estimates for Corvus Pharmaceuticals, Inc. (C17) traded on the BX Swiss exchange. It details analyst price targets, upcoming earnings reports, past earnings and revenue figures, and company information including employee count and divid", "url": "https://www.tradingview.com/symbols/BX-C17/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:29", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Corvus Pharmaceuticals, Inc. \u2013 NASDAQ:CRVS", "summary": "This article focuses on the enterprise value to revenue forward metric for Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS). It appears to be a financial data point or analysis offered by TradingView, indicating a specific valuation multiple for the company. The content primarily high", "url": "https://www.tradingview.com/symbols/NASDAQ-CRVS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:33", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Corvus Pharmaceuticals, Inc. \u2013 NASDAQ:CRVS", "summary": "This article provides a brief financial data point regarding the \"Price to sales forward\" for Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS). It appears to be an excerpt from a financial data platform, indicating the value and change for this metric, presented without additional det", "url": "https://www.tradingview.com/symbols/NASDAQ-CRVS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T11:09:51", "published_display": "25 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Corvus Pharmaceuticals, Inc. \u2013 NASDAQ:CRVS", "summary": "This article provides the \"Price to book forward\" financial metric for Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS). It lists \"Period,\" \"Value,\" \"Change,\" and \"Change %\" as data points, indicating financial performance. The content is brief and appears to be a data", "url": "https://www.tradingview.com/symbols/NASDAQ-CRVS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T05:42:18", "published_display": "25 Jun 2026 05:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQTjNobXFfdHZQaC1BMElXcGhNVVFsaVhEWHNPb0RDZjI4dnpqYUhVNzZPem1XQnlvYnh1YmVtU1FIaFBCVGRxaXpuYzZrVDNWZjVteW9fM2xQUnlWcThkOHZGcnEzZm9OSGdtWWxXeEFOaENzcW9ocjhReFFaVU44RTZndHZCWk13S1FPcG5oN0k5c1BqLVN5Sk1ZZXM0NUNfMDZJMTJKaENaRUtVUmI5b0U0NTZUdndIcUYwellzWkNGWmdo?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Corvus Pharmaceuticals Inc (CRVS), highlighting analyst ratings, price targets, and past and projected EPS. Based on ratings from 7 analysts, most recommend a \"Buy\" trend for CRVS, with a target price of USD 14.00 and an upside space", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crvs/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:07", "published_display": "18 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Inc (CRVS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Corvus Pharmaceuticals Inc (CRVS), including its PE, PB, PS, and PCF ratios. However, the company has not yet disclosed the relevant data for these valuation metrics. The page also displays the current stock price, market capitalizat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crvs/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:07", "published_display": "18 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buys Additional US$250k In Corvus Pharmaceuticals Stock", "summary": "David Moore, an Independent Director at Corvus Pharmaceuticals, recently bought an additional US$250k worth of stock at US$11.53 per share, increasing his holdings. This transaction marks the largest insider purchase in the last twelve months, indicating continued confidence in t", "url": "https://www.sahmcapital.com/news/content/insider-buys-additional-us250k-in-corvus-pharmaceuticals-stock-2026-06-17", "source_name": "Sahm", "published_at": "2026-06-17T17:40:08", "published_display": "17 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Inc (CRVS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides details on the dividend and stock split history for Corvus Pharmaceuticals Inc (CRVS). It states that the company has distributed $0.00 in dividends over the past five years and reports \"No Data\" for both dividend payouts and stock splits, indicating no such", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crvs/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T03:40:23", "published_display": "17 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Inc (CRVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Corvus Pharmaceuticals Inc (CRVS) based on business segments and regional contributions. However, it indicates that the relevant financial data for such a breakdown has not been disclosed by the company. The", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crvs/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T03:40:23", "published_display": "17 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Corvus Pharmaceuticals, Inc. Insider Trading Activity", "summary": "Corvus Pharmaceuticals director Ian T. Clark received a grant of 15,000 stock options with an exercise price of $11.60 per share, expiring on June 11, 2036. These options represent compensation and will vest on the earlier of the first anniversary of the grant date or the company", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-779203eb094d.html", "source_name": "Stock Titan", "published_at": "2026-06-16T07:09:38", "published_display": "16 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus (CRVS) director awarded options for 15,000 shares at $11.60", "summary": "Corvus Pharmaceuticals director Richard van den Broek was granted options to purchase 15,000 shares of common stock at an exercise price of $11.60 per share. These options will vest in a single tranche on the earlier of one year from the grant date or the company's 2027 annual st", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-e1e6bc06f2c7.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:39:33", "published_display": "16 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) director buys 21,700 shares and receives 15,000-share option", "summary": "Corvus Pharmaceuticals director David Scott Moore purchased 21,700 shares of common stock at $11.5316 per share in an open-market transaction, increasing his direct holdings to 21,700 shares. Additionally, he was granted a stock option for 15,000 shares at an exercise price of $1", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-aaa71e046de8.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:09:38", "published_display": "16 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Corvus (CRVS) receives grant of 15,000 stock options", "summary": "Corvus Pharmaceuticals director Peter A. Thompson has been granted 15,000 stock options with an exercise price of $11.60 and an expiration date of June 11, 2036. These options vest on the earlier of the first anniversary of the grant date or the 2027 annual stockholders\u2019 meeting,", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-a39606e23bf4.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:38", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) director receives grant of 15,000 stock options", "summary": "Corvus Pharmaceuticals director Linda Grais was granted 15,000 stock options with an exercise price of $11.6000 per share, expiring on June 11, 2036. These options will vest and become exercisable 100% on the earlier of the first anniversary of the grant date or the company\u2019s 202", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-7b72de75124d.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:38", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) Is Up 7.3% After Promising Soquelitinib Data And Extended Cash Runway", "summary": "Corvus Pharmaceuticals' stock rose 7.3% following promising Phase 1 results for its oral ITK inhibitor soquelitinib in atopic dermatitis, which also extended its cash runway into Q2 2028. The data showed early efficacy and a clean safety profile, supporting the drug's potential i", "url": "https://www.sahmcapital.com/news/content/corvus-pharmaceuticals-crvs-is-up-73-after-promising-soquelitinib-data-and-extended-cash-runway-2026-06-15", "source_name": "Sahm", "published_at": "2026-06-15T18:41:44", "published_display": "15 Jun 2026 18:41", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corvus-pharmaceuticals-faces-key-soquelitinib-220944054.html", "source_name": "Simply Wall St.", "published_at": "2026-06-14T22:09:44+00:00", "published_display": "14 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPcDV0azZYLXRMTVRWM2VnclJCR3BMbVZWS2R2d3ZSNE5IM29mZkJIMEVQOEZZYXVIVm5xMTBrZGtFMUU5QVhCakYzOXc1c3BZWHY4aF9UVkNDNzV3NnlWMW1hR0czOWZpRFdQUWZDMXhnLUxBUndtLWJhX3FzMEJCRkZDOTRmd3F5MDQ5VmZNb3h4UFJXbkl4UUNWNU95M0NFWnY0?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals (CRVS) posts 2026 annual shareholder meeting voting outcomes", "summary": "Corvus Pharmaceuticals (CRVS) has reported the results of its 2026 Annual Meeting of Stockholders. Key outcomes include the election of Class I directors Richard A. Miller and Linda S. Grais, the ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and n", "url": "https://www.stocktitan.net/sec-filings/CRVS/8-k-corvus-pharmaceuticals-inc-reports-material-event-6cac183592ea.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:40:15", "published_display": "12 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Hikes on Position in Angel", "summary": "Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) announced its participation in a new $13.5 million financing round for its Chinese collaboration partner, Angel Pharmaceuticals Ltd. Corvus, already Angel Pharma's largest shareholder, is investing $5 million to support the development ", "url": "https://www.baystreet.ca/stockstowatch/23444/Corvus-Hikes-on-Position-in-Angel", "source_name": "Baystreet.ca", "published_at": "2026-06-10T02:39:01", "published_display": "10 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRVS - Corvus Pharmaceuticals Inc Stock Price and Quote", "summary": "This article provides a detailed stock overview for Corvus Pharmaceuticals Inc (CRVS), including its current stock price, financial metrics, analyst ratings, and recent news history. It lists key financial data such as market cap, income, sales, and employee count, alongside perf", "url": "https://finviz.com/stock?t=CRVS", "source_name": "Finviz", "published_at": "2026-06-09T14:13:15", "published_display": "09 Jun 2026 14:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China", "summary": "Corvus Pharmaceuticals announced an additional $5 million investment in its Chinese collaboration partner, Angel Pharmaceuticals, as part of a $13.5 million financing round. This funding will advance the clinical development of soquelitinib in China for atopic dermatitis and asth", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corvus-pharmaceuticals-announces-additional-investment-113000611.html", "source_name": "Market source", "published_at": "2026-06-09T14:09:54", "published_display": "09 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$13.5M bet on soquelitinib: China eczema and asthma trials move ahead", "summary": "Corvus Pharmaceuticals is investing $5 million in a new $13.5 million financing round for its China partner, Angel Pharmaceuticals. This investment will support the development of soquelitinib for atopic dermatitis and asthma in China, funding an ongoing Phase 1b/2 atopic dermati", "url": "https://www.stocktitan.net/news/CRVS/corvus-pharmaceuticals-announces-additional-investment-in-angel-xu1c8ylvg7oo.html", "source_name": "Stock Titan", "published_at": "2026-06-09T11:39:24", "published_display": "09 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness", "summary": "Corvus Pharmaceuticals (CRVS) has seen significant short-term share price declines despite strong long-term gains, leading to investor questions about its valuation. While a narrative fair value of $35 suggests it's 65.5% undervalued, the P/B ratio at 4.2x (compared to an industr", "url": "https://www.sahmcapital.com/news/content/assessing-corvus-pharmaceuticals-crvs-valuation-after-strong-one-year-gains-and-recent-share-price-weakness-2026-06-02", "source_name": "Sahm", "published_at": "2026-06-02T11:39:50", "published_display": "02 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corvus-pharmaceuticals-present-2026-jefferies-200100281.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T20:01:00+00:00", "published_display": "20 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust", "summary": "Dr. Richard A. Miller, President and CEO of Corvus Pharmaceuticals, Inc. (CRVS), reported indirect open-market purchases of 6,932 shares of the company's common stock through the Miller-Horning Family Trust. These transactions, which occurred on May 18, 2026, involved purchases a", "url": "https://www.stocktitan.net/sec-filings/CRVS/form-4-corvus-pharmaceuticals-inc-insider-trading-activity-395e720756a3.html", "source_name": "Stock Titan", "published_at": "2026-05-20T20:40:35", "published_display": "20 May 2026 20:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNQTJlYmxwUk1rUXJ5QUdHV3lMSlJMR1k3ZkJ1WHd5U0M3TnhsVlUwVW5aWExubEJEdU03RHB0a1NTN19FV1ltUDhEUE1oc3Y3R002UXNFcmR1SkhEc3IwSm5WM0RjRFpUZk5yS1Zra1g5SWdJT1VpeHVSUFhDMEhvOHA2eEpBd0FFWUNxQW5QV21NdkxTNk9NRG5TQjB1Q0g5ZkpyOUdJbHE3ZWhmbWhyVnh6NHFOa2x3VmJ5VDNB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Boxer Capital\u2019s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech\u2019s Next Phase", "summary": "", "url": "https://finance.yahoo.com/m/40edc832-292e-35a2-abd5-ebf64753a5d0/boxer-capital%E2%80%99s-%2418-million.html", "source_name": "Motley Fool", "published_at": "2026-05-17T20:46:06+00:00", "published_display": "17 May 2026 20:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/corvus-pharmaceuticals-presents-soquelitinib-phase-110000712.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:00:00+00:00", "published_display": "14 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus drops on trial data for eczema therapy (CRVS:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQVGlsTlBxT0tKZUMwYW1RV0JhMUxFWjlpYjZqY05STnp5R0p6akRFTmU4cUtfeXE0SnpDVUtQZXllNE9PbVZEMGkxajlJV0ZfRl9qWGZleDFDbWkwX2JnZzIySFVtenBOaVg1ZU9Mc00xb2V3MHo2N183MzJkMzhtbUJn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Corvus Pharmaceuticals (CRVS) After A 335% One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNaVJuamRPSllQQzBZbVIzWllQa1h3anNRX1dIWFBrS19hSkdLb2FhMUZZaDk4SmJWMC1tUTBEcUliaFliY180N3Jta3ZTcFBFdHVPaW9mdVBZYnVWaFVhVDQ0OEExRXIwSUhXMXNWY2NnUGJBQU52bmZzLVFNaEJNUXlDWWNZREFHc25wbENxb0MzVjY2TzNoWTdZaDl3Z3paOXNfdlNFRno5ZFd6TXh6Q1M5cVFMb3RJUm1HSHoyUG5OVTJJTTkxcTRva2Y5NnZueGZ1cG1kT1JSNUViMkRLRURRLXB4R01PSFo1S3FqONIB9AFBVV95cUxNTjFVT0N5MlNFR3NHWkNTWENCdGNFMkVXUGd2UGxqWENPc1M2Yi1uanNXek9oTUhzOEd2a3c4aEFMVWN3NDlTcnZVeDczb1czY2ZvazJTc3YtWkNHZUpRa3prT2hKMlZBUmZPV1RGNWZLUlRYaldITjBBZ1ZYSVRkRXoyTEg5R1pfTFBUM2VSQ3YxN01TX092OWRwc2FYaTJOd2xsTjJ0MW5wYUlMcWZnQThocWdKbDRkRnYxSmMxaFBXdG42Nk93UGxnUHZEdS1wQmFKZUxuQ05mcjFuTzQ0QndZR1BxU2dVZEdLa1E5X3FRSk1M?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZjFBNTA2c3BXTmtVTnVzR0dRRmVDcDczQzdhXy1yVlZWN2ZnVDZFTmc5OUUtS045cl9iNFU2b1hqdkZ5aHFLX1VlclJVR1NFRThuM015TUo2cHlDVDRNeEJScHdpcE8xVzRKaXlKNGlBcjNOVThwZjIwM0o0Z2xMX3JhblV3dGpPTFUzX3dUblRfS2hqdzdVUDF4NTV3QTJN?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_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?oc=5", "source_name": "The Manila Times", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/corvus-q1-earnings-snapshot-204438527.html", "source_name": "Associated Press", "published_at": "2026-05-07T20:44:38+00:00", "published_display": "07 May 2026 20:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs initiates Corvus Pharmaceuticals stock with buy rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPdE1GRzlnUWQySWxCcUVzNktBYjF0WkF1YUF4eHY3Zm11dkgxSWtuY2JOQUhZc2ttaHQ5WDhoNG5QbGYyYk1MV1BxdTg4cGxiek9YdDBCRmM5NVBnai1oZkNGRGxBN2pQQUpJdmp6NVlxTzNjWHJDY2poaUFlNDJieWxqZi12TkRuSVR5UGNnV0lvY0JicXEwOV93RE85bFVNemQ0RVhvX2VZQkxjQnBoWFgzRDVtaS14QVZrOU40VmhWUUdlX3g4?oc=5", "source_name": "Investing.com", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus jumps as Goldman Sachs initiates at Buy on lead asset", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQcHQ0NW1fdklOTjVMSGk3RF9Kd05QbE1VUlBOdWV3YkZ0TnYwVGxIYVVpTmE1d01xOWhMa0JvZk1jTzkzX2J6c05lZXZIczZ0X2QzU2U0dEZBeEhsZS1tc2ZIakNDNTB5cEQyaFMxSkNlanU2QVg1N1BuZGlMbnlkRVJmZTFFR2s2VDU2OVU1ekNORlN4RGJKVnZXa2FWQnM?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Trials Progress And Cash Raise Reframe Soquelitinib Risk Reward Profile", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever \u2014 What Went Wrong?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOeXBrZ0ZtREpkbk50aEZpbnd6M3hiUzNFY2ktWkZUSGJ0dGFDbUR6SW9RU1hvM0tfbFdzSS1rZ2drZ2lHNDlzQUc3bWw0Yi1Hd0FaS3c1UzB6YUtvNFZJb2RkemlNZTBfeXNIZGN6bGxhYUxicnFoTlI4eGxoeklaTDl2X2s1cWM0Rno3VXNkY1E3TTJmRnFjZmx3MEFrY29yeXNsNkc5SmNBd1dIcl8zdnVpZjREWGZCNDh5RlRTQVlYQQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYVJ0U1hGTmJZWlhVRW5MTnpWN2FoUjkwWEFPOHBiLWVFa1FJZXNad0d0dTB6OEJjTklOeHZfa2xvb1BfTDAxNjkxQVoxX0FXQTh4ekxjcmkteHNpal9DZlo4ckZwWFNCQ3dRc09MSm5hVXc5OS1HSTRnM3Q1UjhiYWpKdjBVSGJwMTJhaHVORjltQUR1?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNRTRzbDVaNzROU1NFRUhpSFpnMGhuc0xaNEVnc19MMkZHUjhodjFHQ295eUdxUl9KOUV6RFdfeUNUYzZNT2owY3ZraWdKVGVZdnBuRkk2VzlsYTg3azJ5ZHZyVE42SWFVSzNCWE9EUzFhT1NsdjhPVk54bmNuU2s3Zkl4ZkV1QjcxNXQ1Sm1tUQ?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNS01ZNEtTeGtuWTFNYWlXQWVDY180Tjc1a1F3MFFRQXZxSUFIdlJnQldZZGxWcjZMVEE2dHVBd3lSTlRNUjF3ZGJUOTBqOTFRSjcwa1ctVGdOekNtYmxSektkLWtoRXZwWE9FNHFwV095b2M3dXk1Yl8xTGExM1JVYXRlcVBzYlFG?oc=5", "source_name": "Market source", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQczAzanFtdUpvY0JzYlZSZFVNeWtrZlh3bXZDVDBzU0VaVS1hdm5hWExTN2xZWjlRUHB1aDE4VDQ3Q1lhbkJCZVh1cVR1X1NTYTdqTUJSMWUyZmhkYTNFSzR4bjZQSTFCVG5IMjJ2cmpnYUxXYld3V1hkOGRvN0tEbTZ1ZTBZXzZ6YjNiUGl1aXJfdFN1QkxNR2ZoN3pIYlJNWG5EOG4yNkstM05jNWcwWUQ5ZW5sS2c0OXpyUDZn?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-22T11:35:23+00:00", "published_display": "22 Jan 2026 11:35", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Corvus Pharmaceuticals (CRVS) Valuation After Positive Soquelitinib Phase 1 Atopic Dermatitis Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNV3E4b3k4bE5TNWFrWUhoN2Z1RV9sZmpmenE3Si05c01NUVl3SWhzOTNmX3B5UFRmSko3RG51TXRIMHBpWjlQcERmRjFzNXVTeXZiM19SSFU1TWs2X21BcVlic1pGUWs2Q1hFYXBKeXhyVUxoZnpUU1ZCd0JYS29tbWdOaVUtNEpBR2dGdmlVbjAwc2Z2dEpPaQ?oc=5", "source_name": "Market source", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What made Corvus stock double on Tuesday and is it sustainable?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVUtBVnQyeVZIbzFBMzF5cHQtY2N6dTVxa1RhdXdldjRrWTBEcU03QS14OHdWYy1EcGZiQllWRGdKWDZJUDIxWVdJdVViVVpIN3lHV0VPR0k1RXpHQVhqcExkRTBVNWZQMzlKdnlXY05WbWpybDRQUm9rZ1gzUjdCd2dnR054OVU5Z1BvZUJWSTNjbS1yTkh4U1hlVHhjS0dVTVVHbngtU2JpYWZoQ2dZSTV5VnhvTFIxaHEw?oc=5", "source_name": "TradingView", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corvus Pharma stock falls after announcing $150 million offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPOUtvZ2VKbHNUV3I2QnJGdHFQMXpkRS1kM3hXNkZsLUdLUmtWSk10MTYxTE85X21IZHVXajdYQUZLR2JqTG5MT2VycTRtc3oycmlxQ0VidWtMUHhXa2VTdjBYOVFUY21EZGtoa3A2WE56V2VzdEp6X0JheEVyQURDYkxQU2xxR1J4b3hzZkhyWWcyUDZEVmw0RUF1VGNQd3JTajNxM0h6Q3hKeWhOcFMzd2VLRmZxdmgtczNwWjVvZWMyYnc?oc=5", "source_name": "Investing.com", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Both retail investors who control a good portion of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) along with institutions must be dismayed after last week's 9.3% decrease", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOX19hLTZzS3JLYlc4Y0RISElxdHloOGIwbU5HWmJ5MExib05YRUFOWXFtUkFPZ1QzRld6MW8ybUlEbERhVlpmZlBRWm9jNFFjd3Axb0FiZTV1aWs0NGdPRmoySTM5aFBjaE5vQkRfck5Cc0lnUnZvNVUyM3QyYW50cV9XSXFXd29BbVh4LUFjNFEwNE93OWUwVGxmYlNyWEp3THRickgxbzZtUW55elZfTE9uV1lIaGV1Q2FocW03cGw0ekpILV8zRG5zb2paMTY4ekxXenB0TkFNWi1oMFcyMy10OUloVUVOMC1WYtIB8gFBVV95cUxON0RCYWJ4d0xVa3doS1BSUVVhVDRncDBiM1ZLaTBSM3dzY3JJMVROdzA0RDY5a2M1cmhoX1VDZ3dXejNjTkhsOGVtR1VNdkI4S3lpRGRoMDliOGVObEFlYzl5d2JnTW85ZlJ6Rm8xNTIzWDkwcnpKVW5TZnd6T1ZyZDJUS2JUdklMVkdGYzVQR1NFX20zNjdrVUFPcGpyeS1TaEdwUlRpU21KbDhrUWl3Yy1HOFJwZXBtRDV1NXlKRGVnN3FyOFpxRjk3a0R4UUZfbElKUGZBWDhEOXJKNjd6R0J5azVtNS1UNzlkbDVoejM5QQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 60, "sentiment_summary": {"positive": 23, "negative": 4, "neutral": 33, "score": 57, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 20.3, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 10.11, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 15.67, "latest_week": "2026-07-10", "one_week_move": 2.9, "four_week_move": 31.3, "twelve_week_move": -6.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.410299, "market_dynamics_buy_signal": false, "relative_strength": 23.346451, "fair_value_gap": 162.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.2553, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.9% over one week, +31.3% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "Sahm", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "Quartr", "count": 3}, {"label": "Seeking Alpha", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.9% over one week, +31.3% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Corvus Pharmaceuticals (CRVS) Proxy filing Summary"}], "updated_at": "2026-07-17T07:45:35.809482+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}